SPRC (SciSparc) Price-to-Funds-From-Operations: (As of Sep. 09, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SPRC SciSparc Ltd SPRC
41 GF Score
Price $5.20
GF Value $3.01
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is SciSparc Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.

SPRC
41GF Score
SciSparc Ltd SPRC
Price-to-Funds-From-Operations is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is SciSparc (SPRC) Overvalued in 2026?

Based on GuruFocus' analysis, SciSparc stock appears to be overvalued. The current stock price of $5.20 is trading 72.8% above its estimated GF Value™ of $3.01. GuruFocus considers SciSparc to be Significantly Overvalued.

Key valuation signals for SPRC:

  • Price-to-Funds-From-Operations:
  • GF Value™: $3.01 vs. price of $5.20 (72.8% above fair value)
  • GF Score™: 41/100 with 7 warning signs

No single metric tells the full story. See the SPRC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


SciSparc Business Description

Address 20 Raul Wallenberg Street, Tower A, 2nd Floor, Tel Aviv, ISR, 6971916
SciSparc Ltd is a specialty clinical stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two operating reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company's operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.
41GF Score

Get the complete analysis for SPRC

Price-to-Funds-From-Operations is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.20
Price
$3.01
GF Value